- Home
- HIVE vs PHAT Comparison
HIVE vs PHAT Comparison
Compare HIVE & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HIVE
- PHAT
- Stock Information
- Founded
- HIVE 1987
- PHAT 2018
- Country
- HIVE Canada
- PHAT United States
- Employees
- HIVE N/A
- PHAT N/A
- Industry
- HIVE
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- HIVE
- PHAT Health Care
- Exchange
- HIVE Nasdaq
- PHAT Nasdaq
- Market Cap
- HIVE 527.8M
- PHAT 539.5M
- IPO Year
- HIVE N/A
- PHAT 2019
- Fundamental
- Price
- HIVE $3.35
- PHAT $7.61
- Analyst Decision
- HIVE Strong Buy
- PHAT Strong Buy
- Analyst Count
- HIVE 6
- PHAT 4
- Target Price
- HIVE $7.42
- PHAT $23.00
- AVG Volume (30 Days)
- HIVE 9.6M
- PHAT 984.7K
- Earning Date
- HIVE 02-11-2025
- PHAT 11-07-2024
- Dividend Yield
- HIVE N/A
- PHAT N/A
- EPS Growth
- HIVE N/A
- PHAT N/A
- EPS
- HIVE N/A
- PHAT N/A
- Revenue
- HIVE $123,022,000.00
- PHAT $26,270,000.00
- Revenue This Year
- HIVE N/A
- PHAT $7,622.43
- Revenue Next Year
- HIVE N/A
- PHAT $236.87
- P/E Ratio
- HIVE N/A
- PHAT N/A
- Revenue Growth
- HIVE 55.97
- PHAT N/A
- 52 Week Low
- HIVE $2.18
- PHAT $6.07
- 52 Week High
- HIVE $5.54
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- HIVE 46.58
- PHAT 38.09
- Support Level
- HIVE $2.76
- PHAT $7.33
- Resistance Level
- HIVE $3.14
- PHAT $8.34
- Average True Range (ATR)
- HIVE 0.25
- PHAT 0.56
- MACD
- HIVE 0.01
- PHAT 0.17
- Stochastic Oscillator
- HIVE 42.45
- PHAT 36.94
About HIVE HIVE Digital Technologies Ltd.
HIVE Digital Technologies Ltd is in the business of providing infrastructure solutions in the blockchain industry. It focuses on the mining and sale of digital currencies. Its geographical segments include Canada, Sweden, Iceland, Switzerland, and Bermuda, out of which the majority of the revenue comes from Bermuda.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.